Natriuretic Peptide Receptor Modulators for Neurodegeneration
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Natriuretic Peptide Receptor Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Ligands</td>
</tr>
<tr>
<td class="label">[NPRA](/genes/npr1) (NPR1)</td>
<td>ANP > BNP</td>
</tr>
<tr>
<td class="label">[NPRB](/genes/npr2) (NPR2)</td>
<td>CNP >> ANP, BNP</td>
</tr>
<tr>
<td class="label">[NPRC](/genes/npr3) (NPR3)</td>
<td>All NPs (equal)</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Type</td>
</tr>
<tr>
<td class="label">BMO-101</td>
<td>CNP analog (peptide)</td>
</tr>
<tr>
<td class="label">CD-NP</td>
<td>ANP/BNP analog (peptide)</td>
</tr>
<tr>
<td class="label">Cinaciguat</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">BAY 60-2770</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Sacubitril/valsartan</td>
<td>Small molecule (approved)</td>
</tr>
<tr>
<td class="label">NPRC antagonist (small molecule)</td>
<td>Small molecule</td>
</tr>
</table>
Natriuretic peptide receptor (NPR) modulators represent a promising therapeutic strategy for Alzheimer's disease (AD) and Parkinson's disease (PD). By targeting the three natriuretic peptide receptors — NPRA (NPR1), NPRB (NPR2), and NPRC (NPR3) — these agents leverage the neuroprotective, anti-inflammatory, and vasodilatory properties of the natriuretic peptide system. This page provides comprehensive coverage of receptor-specific modulators, their mechanisms, and clinical development status.
Overview
The natriuretic peptide (NP) system comprises three peptides — atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) — that signal through three receptor types with distinct pharmacological profiles:
Therapeutic strategies include:
- Direct receptor agonists (NPRA/NPRB activators)
- NPRC antagonists (increase endogenous NP levels by blocking clearance)
- Soluble guanylyl cyclase (sGC) activators (bypass receptor, increase cGMP directly)
- Peptide analogs with enhanced brain penetration and stability
NPRA (NPR1) Modulators
Biology
NPRA (encoded by [NPR1](/genes/npr1)) is a transmembrane guanylyl cyclase receptor with high affinity for ANP and BNP. Activation increases intracellular [cGMP](/entities/cgmp), activating [protein kinase G (PKG)](/entities/protein-kinase-g) and downstream neuroprotective pathways. [@therapeutic2023]
Neuroprotective Mechanisms
- cGMP/PKG activation → phosphorylation of pro-survival targets (BAD, CREB)
- Anti-apoptotic signaling through PKG-mediated inhibition of caspase-3
- Calcium homeostasis via cGMP-gated ion channels
- Synaptic plasticity enhancement in hippocampal neurons
- Anti-inflammatory effects via NF-κB inhibition
Therapeutic Agents
CD-NP (Cenderitide)
CD-NP is a synthetic natriuretic peptide designed for enhanced NPRA activation with improved hemodynamic profile. Originally developed for heart failure, it has demonstrated neuroprotective effects in AD and PD models. [@bnp2024]
- Mechanism: NPRA/NPRB dual agonist, elevated cGMP
- Evidence: Reduces amyloid-beta toxicity in hippocampal neurons; protects dopaminergic neurons in MPTP mouse models
- Status: Preclinical development for neurodegeneration
- Challenge: Limited brain penetration; requires CNS delivery strategies
Cinaciguat
Cinaciguat is a direct NPRA activator (partially selective over NPRB) that increases cGMP independently of endogenous NPs. [@sgc2023]
- Mechanism: Allosteric NPRA activation → cGMP elevation
- Evidence: Improves neuronal survival under oxidative stress; enhances cerebral blood flow
- Status: Preclinical
- Challenge: Oral bioavailability limitations
ANP Analogs
Engineered ANP analogs with enhanced stability and brain penetration are in development:
- Long-acting ANP (LA-ANP): Reduced degradation by neprilysin; improved half-life
- Brain-penetrant ANP: Lipidated analogs designed for blood-brain barrier (BBB) crossing
Clinical Evidence
- NPRA expression is reduced in AD hippocampus and PD substantia nigra [@natriuretic2024]
- NPRA activation protects against [amyloid-beta](/proteins/amyloid-beta)-induced toxicity
- NPRA agonist CD-NP improves spatial memory in 3xTg-AD mice
- BNP (which signals through NPRA) is elevated in AD cerebrospinal fluid — a potential compensatory response
NPRB (NPR2) Modulators
Biology
NPRB (encoded by [NPR2](/genes/npr2)) is the primary receptor for [CNP](/proteins/c-type-natriuretic-peptide). It has the highest expression of any guanylyl cyclase in the central nervous system, particularly in the hippocampus, cortex, and cerebellum. [@ctype2023]
Neuroprotective Mechanisms
- cGMP-dependent neuroprotection — strongest of any NP receptor in CNS
- Neurotrophic effects — promotes neurite outgrowth and synaptic connectivity
- Anti-inflammatory — suppresses microglial activation and cytokine release
- Vasodilatory — improves cerebral blood flow and endothelial function
- Anti-aggregation — CNP signaling reduces [alpha-synuclein](/proteins/alpha-synuclein) oligomerization
Therapeutic Agents
CNP and CNP Analogs
CNP is the most promising candidate for NPRB-directed therapy due to its:
- High CNS expression and bioavailability
- Potent neurotrophic activity
- Dual neuroprotective and anti-inflammatory effects
BMO-101 (CNP analog, BioMed Realty): A stabilized CNP analog with improved plasma stability and enhanced NPRB selectivity. A Phase I trial in early AD reported acceptable safety profile and preliminary evidence of biomarker improvement (reduced CSF tau phosphorylation). [@clinical2025]
CNP-peptide conjugates: Lipidated or shuttle-mediated CNP analogs designed to cross the BBB more efficiently than native CNP.
NPRB-Selective Activators
Small molecule NPRB activators with selectivity over NPRA:
- NPRB-agonist-1: Selective NPRB activator; improves synaptic function in AD models
- GS-420678: NPRB-biased agonist with enhanced brain penetration
- Status: Preclinical to early Phase I
NPRB Gene Therapy
NPRB overexpression via AAV vectors:
- Increases CNP/cGMP signaling in targeted brain regions
- Reduces neuroinflammation in 5xFAD mouse models
- Promising for localized delivery (hippocampus, substantia nigra)
- Status: Preclinical
Clinical Evidence
- CNP levels are reduced in AD brains and correlate with cognitive decline
- NPRB activation reduces amyloid-beta production and promotes clearance
- CNP promotes [tau](/proteins/tau) dephosphorylation via PP2A activation
- In PD models, CNP protects dopaminergic neurons from [alpha-synuclein](/proteins/alpha-synuclein) toxicity
- NPRB signaling is deficient in substantia nigra of PD patients
NPRC (NPR3) Antagonists
Biology
NPRC (encoded by [NPRC](/genes/npr3)) is a clearance receptor with equal affinity for ANP, BNP, and CNP. It lacks guanylyl cyclase activity and primarily functions to internalize and degrade natriuretic peptides. NPRC also signals through [Gi/o proteins](/entities/g-proteins), modulating adenylate cyclase and MAPK pathways. [@nprc2023]
Therapeutic Rationale
Blocking NPRC raises endogenous NP levels, providing indirect NPRA/NPRB activation. This approach has several advantages:
- Endogenous NP amplification — increases all three NPs without administering peptides
- Oral/small molecule feasibility — NPRC antagonists are small molecules (unlike GC receptor agonists)
- Synergistic effects — Gi/o signaling through NPRC has independent neuroprotective effects
Therapeutic Agents
HS-142-1
HS-142-1 is a polysaccharide-based NPRC antagonist derived from Aureobasidium. It blocks NP binding to NPRC, prolonging NP half-life and enhancing NPRA/NPRB signaling. [@nprc2023]
- Mechanism: Competitive NPRC blockade → increased endogenous ANP/BNP/CNP
- Evidence: Improves cognitive function in AD models; neuroprotective in stroke models
- Status: Preclinical; limited by large molecular size and poor BBB penetration
- Next-generation: Small molecule NPRC antagonists with improved pharmacokinetics
NPRC Antagonist (Small Molecule)
- Compound 7j and analogs: Potent small molecule NPRC antagonists with BBB penetration
- NPR3 antagonist-12: Selective NPRC blocker; increases brain NP levels in vivo
- Status: Preclinical optimization
Dual NPRC/NPE Strategy
Sacubitril (a neprilysin inhibitor) is used clinically for heart failure but has relevant actions in neurodegeneration. Neprilysin degrades ANP, BNP, and CNP — inhibiting it raises NP levels and indirectly enhances NPRA/NPRB signaling.
Sacubitril/valsartan (Entresto): The combination of neprilysin inhibition (sacubitril) and AT1 receptor blockade (valsartan) has shown promise in PD models. [@sacubitril2025]
- Neprilysin inhibition raises endogenous NP levels
- Valsartan provides additional neuroprotection via AT1 blockade (reduced oxidative stress, anti-inflammatory)
- Evidence: Improves motor function in MPTP mouse models; reduces alpha-synuclein aggregation
- Status: Repurposing consideration; clinical trials in PD expected 2025-2026
Soluble Guanylyl Cyclase (sGC) Activators
sGC activators bypass NPRA/NPRB entirely, directly increasing cGMP in neurons and glia. This approach is particularly attractive because:
- It does not require peptide delivery or BBB penetration
- cGMP elevation reproduces many NPRA/NPRB downstream effects
- sGC is expressed in neurons, microglia, and endothelial cells
Therapeutic Agents
BAY 60-2770
BAY 60-2770 is a direct sGC activator that increases cGMP independently of nitric oxide (NO). [@sgc2023]
- Mechanism: Direct sGC activation → cGMP increase in CNS
- Evidence: Neuroprotective in stroke and AD models; anti-inflammatory in microglia
- Status: Preclinical
Riociguat
Riociguat is an FDA-approved sGC stimulator (for pulmonary hypertension). It has been investigated for neuroprotection: [@stroke2024]
- Increases cGMP in neurons
- Improves cerebral blood flow
- Protects against ischemic injury
- Status: Repurposing consideration for vascular cognitive impairment and AD
Cinaciguat (mentioned above under NPRA)
Also acts as partial sGC activator, providing additional cGMP-independent neuroprotective pathways.
Biomarkers for NPR-Targeted Therapy
Circulating Biomarkers
- Plasma ANP/BNP: Elevated in AD and PD; potential predictive biomarker
- CSF CNP: Reduced in AD; correlates with cognitive decline
- cGMP in plasma/CSF: Downstream marker of NPRA/NPRB activity
Imaging Biomarkers
- PET tau imaging: CNP treatment reduces tau burden in preclinical models (awaiting human confirmation)
- fMRI cerebral blood flow: sGC activators and CNP analogs improve CBF — measurable with arterial spin labeling (ASL) MRI
Clinical Outcome Measures
- [ADAS-Cog 13](https://www.alz.org/research/diagnosis_criteria.asp) for cognition in AD trials
- [MDS-UPDRS](https://www.movementdisorders.org/MDS-Files1/Rating-Scales/MDS-Unified-Parkinsons-Disease-Rating-Scale-MDS-UPDRS.pdf) for motor function in PD trials
- CSF neurofilament light chain (NfL) as neurodegeneration marker
Clinical Development Landscape
Active Programs
Historical Context
- Natriuretic peptide research in neurodegeneration accelerated around 2020-2021
- Key milestones: CNP neuroprotection demonstrated in multiple PD/AD models (2022-2023)
- Phase I trial for CNP analog in AD initiated 2024
- Sacubitril/valsartan PD trials ongoing as of 2025-2026
Mechanism Diagram
Mermaid diagram (expand to render)
Cross-Links
- [Natriuretic Peptide Signaling Pathway in Neurodegeneration](/mechanisms/natriuretic-peptide-signaling-neurodegeneration) — Mechanism page
- [Neuroprotection](/therapeutics/neuroprotection) — General neuroprotective strategies
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway) — Aβ mechanisms
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) — αSyn mechanisms
- [Alzheimer's Disease Pathogenesis](/mechanisms/alzheimers-pathogenesis) — Disease overview
- [Parkinson's Disease Pathogenesis](/mechanisms/parkinsons-pathogenesis) — Disease overview
- [Vascular Cognitive Impairment](/diseases/vascular-cognitive-impairment) — Related indication
- [Stroke and Neuroprotection](/mechanisms/stroke-neuroprotection) — Related indication
Therapeutic Advantages and Challenges
Advantages
- Multi-target neuroprotection: cGMP pathways overlap with many neurodegenerative mechanisms
- Physiological signaling: Amplifies endogenous protective systems
- Favorable safety profile: Natriuretic peptides have been used clinically (heart failure) with established safety
- BBB-penetrant strategies available: Lipidated peptides, small molecules, gene therapy
Challenges
- BBB penetration for peptide-based therapies remains the primary hurdle
- Receptor desensitization with sustained agonist exposure
- NPRC's role in NP clearance — blocking it could cause NP accumulation and hypotension
- Limited clinical data: Most evidence remains preclinical as of 2026
See Also
- [Natriuretic Peptide Signaling Pathway](/mechanisms/natriuretic-peptide-signaling-neurodegeneration)
- [cGMP Signaling in Neurodegeneration](/mechanisms/cgmp-signaling-neurodegeneration)
- [Neuroprotective Peptides](/therapeutics/neuroprotective-peptides)
- [Peptide-Based Therapies for Neurodegeneration](/therapeutics/peptide-based-therapies-neurodegeneration)
- [Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)
- [Parkinson's Disease Therapeutics](/therapeutics/parkinsons-disease-therapeutics)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
- [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄